Cart
sales@molnova.com
Dabrafenib Mesylate
CAS No. 1195768-06-9
Dabrafenib Mesylate( GSK2118436 Mesylate,GSK 2118436B )
Catalog No. M22046 CAS No. 1195768-06-9
Dabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 36 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 65 | In Stock |
|
| 50MG | 77 | In Stock |
|
| 100MG | 105 | In Stock |
|
| 500MG | 214 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDabrafenib Mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionDabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
-
DescriptionDabrafenib Mesylate is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).In human endothelial cells, Dabrafenib inhibits the release of HMGB1 and down-regulates the HMGB1-dependent inflammatory response by enhancing the expression of cell adhesion molecules (CAM).
-
In Vitro——
-
In Vivo——
-
SynonymsGSK2118436 Mesylate,GSK 2118436B
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf
-
Research AreaCancer
-
IndicationLow Grade Glioma (LGG) of Brain With BRAF AberrationHigh Grade Glioma (HGG) of the Brain With BRAF AberrationLow Grade Glioma of Brain With Neurofibromatosis Type 1
Chemical Information
-
CAS Number1195768-06-9
-
Formula Weight615.67
-
Molecular FormulaC24H24F3N5O5S3
-
Purity>98% (HPLC)
-
SolubilityDMSO:34 mg/mL (55.22 mM)
-
SMILESCS(O)(=O)=O.CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9.
molnova catalog
related products
-
B-Raf IN 2
B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research.
-
Locostatin
Locostatin is a potent and cell permeable inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.Locostatin treatment resulted in the activation of the mitogen-activated protein kinase (MAPK) signal pathway (ERK phosphorylation), providing a powerful validation of our targeting protocol.?
-
GNE-9815
GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
